Alpha Teknova Inc. (TKNO)
TKNO trades on Nasdaq in Health Care, Biotechnology: In Vitro & In Vivo Diagnostic Substances. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$8.22
-5.52% on the day
Market cap
$441.3M
Small cap
Revenue · 2025
$40.5M
+7.4% on 2024
Net income · 2025
-$17.3M
-42.6% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | TKNO on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Country | United States |
| IPO year | 2021 |
| SEC CIK | 0001850902 |
| SEC industry code | In Vitro & In Vivo Diagnostic Substances |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $40.5M |
| Net income | -$17.3M |
| Operating income | -$17.0M |
| Net margin | -42.6% |
| Operating margin | -41.9% |
| Revenue growth | +7.4% |
| Cash | $5.9M |
| Total assets | $103.6M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 10.9× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2025-07-10 |
| Latest annual report | 10-K | 2026-03-02 |
| Latest quarterly / interim | 10-Q | 2026-08-06 |
| Latest current report | 8-K | 2026-08-05 |
| Latest proxy | DEFA14A | 2026-04-21 |
Source: SEC EDGAR submissions feed, 217 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -9.9% |
| 1 month | +13.8% |
| 3 months | +47.6% |
| Year to date | +106.6% |
| 1 year | +56.7% |
| From 52-week high | -15.9% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: In Vitro & In Vivo Diagnostic Substances
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| MYGN | Myriad Genetics Inc. | $4.08 | -2.86% | $390.3M |
| NNNN | Anbio Biotechnology | $4.26 | -3.40% | $613.0M |
| ACHV | Achieve Life Sciences Inc. Common Shares | $7.00 | -0.85% | $720.3M |
| QDEL | QuidelOrtho Corporation | $14.10 | +6.42% | $966.9M |
| NTLA | Intellia Therapeutics Inc. | $11.91 | -5.33% | $1.7B |
| ICCC | ImmuCell Corporation | $10.79 | +12.40% | $98.0M |
| IMDX | Insight Molecular Diagnostics Inc. | $2.99 | -5.68% | $97.8M |
| CLDX | Celldex Therapeutics Inc. | $28.25 | -4.01% | $2.2B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier